Actinogen’s Daily Cortisol Pill Shows Mixed Alzheimer’s Results
Actinogen’s experimental daily pill showed no statistically significant benefit across an Alzheimer’s trial of 247 patients. A subgroup older than 75 showed a 30% slowing in disease progression. The Australian biotech company plans a larger trial involving 700 patients.

Australian biotech company Actinogen’s daily pill to block cortisol showed mixed results in a 36-week Alzheimer’s trial involving 247 patients in Australia and the US.
The full trial group showed no statistically significant benefit. Patients older than 75, who represented half the group, experienced a 30% slowing in disease progression by the trial’s end.
The experimental drug, emestedastat, is being developed under the brand name Xanamem. It aims to block cortisol production in brain areas linked to Alzheimer’s progression.
Older patients showed a benefit
Participants had mild to moderate Alzheimer’s disease. They took either a daily 10mg dose or a placebo, a treatment with no active drug.
The trial was double-blind, meaning participants and researchers did not know who received the drug during the study. The median age was 75.
Actinogen CEO Dr Steven Gourlay said the lack of a similar benefit in younger patients was disappointing. He said older patients also have higher markers of inflammation.
“Our drug probably is having an effect of lowering inflammation in the brain,” Gourlay said.
He compared the older group’s results with recently approved antibody treatments, which he said reduce progression by between 22% and 27%.
Gourlay said a low-dose tablet would cost significantly less and have fewer side effects than current therapies.
Professor Michael Woodward, honorary medical adviser for Dementia Australia, said mixed results were typical in dementia drug trials. He said the findings could help shape the next phase of testing.
A different target for treatment
Cortisol is a stress hormone. Its production is normal and necessary, though researchers hypothesize that persistently high levels can become toxic to brain cells.
Research has linked high cortisol levels to cognitive decline. Prolonged elevated cortisol has also been associated with the development of amyloid beta plaques in the brain.
Other Alzheimer’s treatments target those plaques. The antibody drugs donanemab and lecanemab work by reducing their buildup.
Other drugs in development target tau, abnormal protein clumps that build up in brain cells and disrupt signaling and cell transport. Researchers debate whether amyloid beta or tau is the main driver of Alzheimer’s.
Next trial planned for 700 patients
Actinogen expects its next trial to involve 700 patients. The company hopes to bring the drug to market in 2030.
Separately, University of Sydney researchers have developed experimental nose drops that boosted cognition and prevented memory loss in mice with genetic mutations for Alzheimer’s.
The drops use mRNA technology and bypass the blood-brain barrier, an obstacle to many drugs entering the brain. Study author Professor Greg Neely said human trials are the next step.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1Gold Silver Price November: Futures Rise Near Yearly Lows

- 2U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 3Michael Clarke Says Sandpapergate Scars Drew Steve Smith to New York

- 42027 NFL Mock Draft Puts Ohio State’s Jeremiah Smith at No. 1

- 5GTA 6 New Zealand Time Trick Is Not Guaranteed to Work

Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists















